[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-330910-105":59,"doc-detail-330910-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circiars-a-potential-plasma-biomarker-for-diagnosing-non-small-cell-lung-cancer","circIARS - a potential plasma biomarker for diagnosing non-small cell lung cancer","","Non-small cell lung cancer (NSCLC) remains difficult to detect early, limiting survival benefits from timely intervention. This study screens differentially expressed circIARS from sequencing data and validates its molecular features using Sanger sequencing, RNase R resistance, agarose gel electrophoresis, and FISH. circIARS expression is quantified by qRT-PCR, and diagnostic performance is assessed with ROC analysis. Plasma collected from postsurgical, chemotherapy, and relapse patients supports prognostic relevance, with expression higher than healthy and many benign or competing cancer groups, decreasing after antitumor therapy and increasing upon recurrence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circiars-a-potential-plasma-biomarker-for-diagnosing-non-small-cell-lung-cancer/330910/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circiars-a-potential-plasma-biomarker-for-diagnosing-non-small-cell-lung-cancer/330910.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was circIARS identified and validated in NSCLC samples?","Question",{"text":112,"@type":113},"circIARS was screened from sequencing results for differential expression. Molecular characteristics were examined using Sanger sequencing, RNase R assay, agarose gel electrophoresis, and FISH.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What methods were used to evaluate circIARS for diagnostic performance?",{"text":117,"@type":113},"Expression of circIARS was measured by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR). Diagnostic value was analyzed using ROC curve-based performance assessment.",{"name":119,"@type":110,"acceptedAnswer":120},"How does circIARS expression change across treatment and disease course?",{"text":121,"@type":113},"circIARS expression is lower after antitumor therapy such as chemotherapy and rises after recurrence. ROC analysis indicates better detection efficiency than traditional markers, and expression correlates with clinicopathological parameters.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},330910,1790142439,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Original Article  \ncircIARS: a potential plasma biomarker for diagnosing non-small cell lung cancer  \nQi Zhang 1,2,3,†, Xinfeng Fan1,2,3,†, Xinyu Zhang2,4, *, and Shaoqing Ju 1,2, *  \n1 Medical School of Nantong University, Nantong University, Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China, 2Medical School of Nantong University, Nantong University, Nantong 226001, China, 3Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China, and 4 Institute of Urology, Lanzhou University Second Hospital; Key  \nLaboratory of Gansu Province for Urological Diseases; Gansu Nephro-Urological Clinical Center, Lanzhou 730030, China †These authors contributed equally to this work.  \n*Correspondence address. Tel: +86-18752116113; E-mail: [zxy6935@163.com](zxy6935@163.com) (X.Z. ) / Tel: +86-513-85052335; E-mail: [jsq814@hotmail.com](jsq814@hotmail.com) (S.J. ) Received 25 September 2023 Accepted 22 December 2023  \nAbstract  \nNon-small cell lung cancer (NSCLC) is one of the most prevalent cancers in the world, and early diagnosis can effectively improve patient survival. Here, differentially expressed circIARS genes are screened from the sequencing results, and their molecular characteristics are examined by Sanger sequencing, RNase R assay, agarose gel electrophoresis (AGE), and fluorescence in situ hybridization (FISH) . Real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) is performed to detect the expression level of circIARS. The diagnostic value of the signature is analyzed using a subject operating characteristic (ROC) curve. Moreover, plasma is collected from postsurgical, chemotherapy, and relapse patients to investigate the prognostic value of circIARS in NSCLC. The expression of circIARS is greater in both the plasma and tissues of NSCLC patients than in those of healthy individuals, and could be used to distinguish NSCLC patients from patients with benign pulmonary disease (BPD), small cell lung cancer (SCLC) patients, and healthy individuals. The expression level of circIARS relatively decreases after antitumor therapy, such as chemotherapy, and relatively increases after recurrence. ROC analysis reveals that circIARS has better detection efficiency than traditional markers. In addition, circIARS expression level is strongly correlated with several clinicopathological parameters. Finally, we tentatively predict the downstream miRNAs or RBP that might bind to circIARS. Plasma circIARS is significantly greater in NSCLC patients and has good stability and specificity as a diagnostic marker, which could aid inthe adjuvant diagnosis and dynamic monitoring of NSCLC.  \nKey words biomarker, circIARS, diagnosis, non-small cell lung cancer, prognosis  \nBackground  \nLung cancer is the leading cause of cancer death in men and women. The burden of treatment for non-small cell lung cancer (NSCLC), the most common type of lung cancer, has become a growing concern [1] . Despite the rapidly evolving prospects for NSCLC treatment, the disease is often diagnosed by local progression or metastasis or is already advanced. In contrast, early detection and treatment of NSCLC can significantly improve survival rates [1] . Among the ancillary diagnostic methods for detecting NSCLC, chest X-ray and sputum cytology often fail to detect NSCLC early; although bronchoscopy is excellent at detecting lung tumors, it is invasive. In addition, although CT is noninvasive and highly sensitive, it is often accompanied by overdiagnosis [2,3] .  \nSeveral studies have confirmed the effects of noncoding RNAs (ncRNAs) and mRNAs on the early screening and biological progression of NSCLC, such as the inhibition of growth, ING5 overexpression, miR-34c-5p/Snail1 inhibition of EMT and lung cancer cell invasion [4], and on the pseudogene DUXAP10 which contributes to gefitinib resistance in NSCLC by inhibiting OAS2 expression [5] . Therefore, the screening of simple an","cbCaibPUYly3uTHX","https://ap.wps.com/l/cbCaibPUYly3uTHX","pdf",1668630,"English","# Abstract\n# Background\n## Limitations of current NSCLC detection methods\n## Role of noncoding RNAs in NSCLC screening and progression\n## Biological features and advantages of circular RNAs (circRNAs)\n## Potential of circRNAs as tumor biomarkers","[{\"question\":\"How was circIARS identified and validated in NSCLC samples?\",\"answer\":\"circIARS was screened from sequencing results for differential expression. Molecular characteristics were examined using Sanger sequencing, RNase R assay, agarose gel electrophoresis, and FISH.\"},{\"question\":\"What methods were used to evaluate circIARS for diagnostic performance?\",\"answer\":\"Expression of circIARS was measured by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR). Diagnostic value was analyzed using ROC curve-based performance assessment.\"},{\"question\":\"How does circIARS expression change across treatment and disease course?\",\"answer\":\"circIARS expression is lower after antitumor therapy such as chemotherapy and rises after recurrence. ROC analysis indicates better detection efficiency than traditional markers, and expression correlates with clinicopathological parameters.\"}]","circIARS - a potential plasma biomarker for diagnosing non-small cell lung cancer | PDF",1789990680,25]